文献速递肿瘤 PET/CT核素与放射性配体治疗

引流途径对前列腺癌淋巴结转移检测的影响:瘤内与前列腺内示踪剂注射用于前哨淋巴结检测的II期随机比较

The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-11-08

这项前瞻性随机II期试验将淋巴结转移风险>5%的前列腺癌患者随机分为瘤内注射组(55例)和前列腺内注射组(58例),比较吲哚菁绿-[99mTc]Tc-纳米胶体注射后前哨淋巴结检测效果。瘤内注射组阳性前哨淋巴结占全部阳性淋巴结的比例显著高于前列腺内注射组(73.7% vs 37.3%,p=0.015),且淋巴结阳性患者更多(42% vs 24%,p=0.045),但无转移生存无差异。作者建议对影像可见肿瘤的患者联合使用瘤内和前列腺内示踪剂注射。

要点

  • 瘤内注射组阳性前哨淋巴结占全部阳性淋巴结73.7%,显著高于前列腺内注射组的37.3%(p=0.015)。
  • 瘤内注射组淋巴结阳性患者42%,显著多于前列腺内注射组的24%(p=0.045),但无转移生存无差异。
  • 瘤内注射未能检出非索引卫星病灶的淋巴结转移,作者建议联合瘤内和前列腺内示踪剂注射。

核心结论

  • 瘤内注射后阳性前哨淋巴结百分比显著高于前列腺内注射。
  • 瘤内注射检出显著更多的淋巴结阳性患者,但未影响无转移生存。
  • 瘤内注射未能检出非索引卫星病灶的淋巴结转移,作者建议对影像可见肿瘤的男性联合使用瘤内和前列腺内示踪剂注射。

研究设计与样本

  • 前瞻性随机II期试验,纳入淋巴结转移风险>5%的前列腺癌患者。
  • 瘤内注射组55例,超声引导下经直肠注射吲哚菁绿-[99mTc]Tc-纳米胶体2个点位各1 mL至肿瘤内。
  • 前列腺内注射组58例,注射4个点位各0.5 mL至前列腺外周带。
  • 术前行淋巴显像和SPECT/CT定位前哨淋巴结,术中联合放射和荧光引导切除前哨淋巴结,随后行扩大盆腔淋巴结清扫和机器人辅助根治性前列腺切除术。
  • 结局指标包括荷瘤前哨淋巴结数、荷瘤淋巴结数、切除淋巴结数、淋巴结转移患者数及4-7年随访的无转移生存数据。

主要发现

  • 瘤内注射组与前列腺内注射组切除前哨淋巴结数无显著差异(5.0 vs 6.0,p=0.317)。
  • 两组组织学阳性前哨淋巴结数无显著差异(28 vs 22,p=0.571)。
  • 瘤内注射组阳性前哨淋巴结占全部阳性淋巴结73.7%,前列腺内注射组为37.3%(p=0.015)。
  • 瘤内注射组淋巴结阳性患者42%,前列腺内注射组24%(p=0.045),无转移生存无差异。
  • 2例(3.6%)瘤内示踪剂注射仅部分覆盖前列腺内肿瘤播散的患者,扩大盆腔淋巴结清扫发现淋巴结转移但无肿瘤阳性前哨淋巴结。

临床怎么用

  • 作者建议对影像可见肿瘤的男性联合使用瘤内和前列腺内示踪剂注射。

局限性

  • 瘤内注射未能检出非索引卫星病灶的淋巴结转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Previous studies indicated that location and amount of detected sentinel lymph nodes (SLNs) in prostate cancer (PCa) are influenced where SLN-tracer is deposited within the prostate. To validate whether intratumoral (IT) tracer injection helps to increase identification of tumor-positive lymph nodes (LNs) better than intraprostatic (IP) tracer injection, a prospective randomized phase II trial was performed. METHODS: PCa patients with a > 5% risk of lymphatic involvement were randomized between ultrasound-guided transrectal injection of indocyanine green-[99mTc]Tc-nanocolloid in 2 depots of 1 mL in the tumor (n = 55, IT-group) or in 4 depots of 0.5 mL in the peripheral zone of the prostate (n = 58, IP-group). Preoperative lymphoscintigraphy and SPECT/CT were used to define the location of the SLNs. SLNs were dissected using combination of radio- and fluorescence-guidance, followed by extended pelvic LN dissection and robot-assisted radical prostatectomy. Outcome measurements were number of tumor-bearing SNs, tumor-bearing LNs, removed nodes, number of patients with nodal metastases, and metastasis-free survival (MFS) of 4-7-year follow-up data. RESULTS: IT-injection did not result in significant difference of removed SLNs (5.0 vs 6.0, p = 0.317) and histologically positive SLNs (28 vs 22, p = 0.571). However, in IT-group, the SLN-positive nodes were 73.7% of total positive nodes compared to 37.3% in IP-group (p = 0.015). Moreover, significantly more node-positive patients were found in IT-group (42% vs 24%, p = 0.045), which did not result in worse MFS. In two patients (3.6%) from whom the IT-tracer injection only partly covered intraprostatic tumor spread, nodal metastases in ePLND without tumor-positive SNs were yielded. CONCLUSIONS: The percentage-positive SLNs found after IT-injection were significantly higher compared to IP-injection. Significantly more node-positive patients were found using IT-injection, which did not affect MFS. IT-injection failed to detect nodal metastases from non-index satellite lesions. Therefore, we suggest to combine IT- and IP-tracer injections in men with visible tumor on imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wit EMK, van Beurden F, Kleinjan GH, et al. The impact of drainage pathways on the detection of nodal metastases in prostate cancer: a phase II randomized comparison of intratumoral vs intraprostatic tracer injection for sentinel node detection. Eur J Nucl Med Mol Imaging. 2021. PMID: 34748059. doi:10.1007/s00259-021-05580-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。